Viridian Therapeutics (VRDN): Q3 2026 10-Q: $75.0M FDA approval milestone received for veligrotug
Viridian got $75.0M FDA approval milestone for veligrotug in June 2026; Q3 royalty accrual $1.9M, $121.6M sale-of-revenue liability.
What this filing says
Viridian's quarterly report covers the period ended September 30, 2026. The filing says the company received a $75.0 million milestone payment after the FDA approved veligrotug in June 2026, and that it carries a $121.6 million liability tied to the sale of future revenue to DRI. For a shareholder, the approval and milestone are the key developments, while the sold-revenue obligation and interest accruals weigh on the balance sheet.
Key figures
- FDA milestone payment received
- $75.0 million
- Upfront from DRI sale of future revenue
- $55.0 million
- Net carrying amount of sale liability
- $121.6 million
- Interest expense, three months ended Sept 30, 2026
- $8.0 million
- Shares outstanding as of November 2, 2026
- 113,558,449 shares
- Net loss, nine months ended Sept 30, 2025
- $222.2 million
Positive for shareholders
- The FDA approved veligrotug in June 2026, which triggered a $75.0 million milestone payment to the company.
- The filing reports net sales royalties of $1.9 million for both the three and nine months ended September 30, 2026.
Negative for shareholders
- The company has a net loss in every period presented, and diluted loss per share equals basic loss per share.
- The sale of future revenue to DRI carries a net liability of $121.6 million and accrues interest expense.
- The filing notes that U.S. administration workforce cuts could affect FDA operations and regulatory timing.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Sale of future revenue:
- An arrangement where a company receives cash upfront in exchange for a share of its future revenue, recorded as a liability on the balance sheet.
- Milestone payment:
- A payment made by a partner to the company when a specified event, such as a regulatory approval, occurs.
- Anti-dilutive:
- A term describing potential share issuances that would reduce loss per share, so they are excluded from the calculation when a company is loss-making.
FAQ
What milestone did Viridian Therapeutics receive in 2026?
The filing says the company received a $75.0 million milestone payment following the FDA's approval of veligrotug in June 2026.
How large is the liability from the DRI sale of future revenue?
As of September 30, 2026, the filing reports a net carrying amount of $121.6 million for the liability related to the sale of future revenue.
Historical context for VRDN
Across the 23 sessions after earlier VRDN headlines, the stock closed higher 14 times and lower 9 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VRDN | SPY |
|---|---|---|---|
| Nov 4, 2026 | Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress | +15.5% | +1.7% |
| Oct 21, 2026 | Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 | +2.6% | +0.5% |
| Aug 6, 2026 | Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results | +6.8% | -0.2% |
| Jun 30, 2026 | FDA Approval for LUMVOA issued to VIRIDIAN THERAPEUTICS INC | -2.2% | +0.8% |
| Jun 29, 2026 | Viridian Therapeutics upgraded by Wells Fargo with a new price targetand 1 other headline that session | +5.0% | +1.6% |
| May 27, 2026 | Viridian Therapeutics to Participate in Upcoming June Investor Conferences | +1.5% | -0.0% |
Keep researching VRDN
- VRDN financial statementsRevenue, profit, cash flow and balance sheet from Viridian Therapeutics Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- VRDN insider tradesEvery buy and sale reported by Viridian Therapeutics Inc. officers, directors and large holders.
- VRDN earnings historyPast Viridian Therapeutics Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Follow VRDN and get a push notification the moment its next story breaks.